APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncology Treatment Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oncology Treatment Drug Market Analysis and Forecast 2026-2032

2 January 2026215 pages

Choose your research edition.

Industry ResearchOncology Treatment Drug Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Treatment Drug Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Oncology Treatment Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Treatment Drug Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Treatment Drug Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Oncology Treatment Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Oncology Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oncology Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oncology Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oncology Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Oncology Treatment Drug include Takeda, Eisai, Teva, Sanofi, Johnson & Johnson, Novartis, Merck KGaA, Roche and Eli Lilly, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Oncology Treatment Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oncology Treatment Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Oncology Treatment Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oncology Treatment Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oncology Treatment Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oncology Treatment Drug revenue, projected growth trends, production technology, application and end-user industry.

Oncology Treatment Drug Segment by Company

Takeda

Eisai

Teva

Sanofi

Johnson & Johnson

Novartis

Merck KGaA

Roche

Eli Lilly

Pfizer

Bayer

Amgen

AbbVie

AstraZeneca

Otsuka

Merck & Co.

Ipsen

Gilead Sciences

Celgene

Bristol-Myers Squibb

Biogen Idec

Astellas

Oncology Treatment Drug Segment by Type

Immunotherapy (Biologic Therapy)

Chemotherapy

Hormonal Therapy

Targeted Therapy

Others

Oncology Treatment Drug Segment by Application

Respiratory/Lung Cancer

Prostate Cancer

Breast Cancer

Gastrointestinal Cancer

Blood Cancer

Others

Oncology Treatment Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Treatment Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oncology Treatment Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oncology Treatment Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Treatment Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oncology Treatment Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Immunotherapy (Biologic Therapy) Major Player Table 3. Chemotherapy Major Player Table 4. Hormonal Therapy Major Player Table 5. Targeted Therapy Major Player Table 6. Others Major Player Table 7. Global Oncology Treatment Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Respiratory/Lung Cancer Major Player Table 9. Prostate Cancer Major Player Table 10. Breast Cancer Major Player Table 11. Gastrointestinal Cancer Major Player Table 12. Blood Cancer Major Player Table 13. Others Major Player Table 14. Oncology Treatment Drug Industry Trends Table 15. Oncology Treatment Drug Industry Drivers Table 16. Oncology Treatment Drug Industry Opportunities and Challenges Table 17. Oncology Treatment Drug Industry Restraints Table 18. Global Oncology Treatment Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 19. Global Oncology Treatment Drug Market Size by Region (2021-2026) & (US$ Million) Table 20. Global Oncology Treatment Drug Market Share by Region (2021-2026) Table 21. Global Oncology Treatment Drug Market Size by Region (2027-2032) & (US$ Million) Table 22. Global Oncology Treatment Drug Market Share by Region (2027-2032) Table 23. Global Oncology Treatment Drug Revenue by Players (US$ Million) & (2021-2026) Table 24. Global Oncology Treatment Drug Revenue Market Share by Players (2021-2026) Table 25. Global Oncology Treatment Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 26. Global Oncology Treatment Drug Key Players Headquarters & Area Served Table 27. Global Oncology Treatment Drug Players, Product Type & Application Table 28. Global Oncology Treatment Drug Players Establishment Date Table 29. Global Players Market Concentration Ratio (CR5 and HHI) Table 30. Global Oncology Treatment Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 31. Global Oncology Treatment Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Oncology Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 33. Global Oncology Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 34. Global Oncology Treatment Drug Revenue Market Share by Type (2021-2026) Table 35. Global Oncology Treatment Drug Revenue Market Share by Type (2027-2032) Table 36. Global Oncology Treatment Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Oncology Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 38. Global Oncology Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 39. Global Oncology Treatment Drug Revenue Market Share by Application (2021-2026) Table 40. Global Oncology Treatment Drug Revenue Market Share by Application (2027-2032) Table 41. Takeda Company Information Table 42. Takeda Business Overview Table 43. Takeda Oncology Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Takeda Oncology Treatment Drug Product Portfolio Table 45. Takeda Recent Development Table 46. Eisai Company Information Table 47. Eisai Business Overview Table 48. Eisai Oncology Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Eisai Oncology Treatment Drug Product Portfolio Table 50. Eisai Recent Development Table 51. Teva Company Information Table 52. Teva Business Overview Table 53. Teva Oncology Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Teva Oncology Treatment Drug Product Portfolio Table 55. Teva Recent Development Table 56. Sanofi Company Information Table 57. Sanofi Business Overview Table 58. Sanofi Oncology Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Sanofi Oncology Treatment Drug Product Portfolio Table 60. Sanofi Recent Development Table 61. Johnson & Johnson Company Information Table 62. Johnson & Johnson Business Overview Table 63. Johnson & Johnson Oncology Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Johnson & Johnson Oncology Treatment Drug Product Portfolio Table 65. Johnson & Johnson Recent Development Table 66. Novartis Company Information Table 67. Novartis Business Overview Table 68. Novartis Oncology Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Novartis Oncology Treatment Drug Product Portfolio Table 70. Novartis Recent Development Table 71. Merck KGaA Company Information Table 72. Merck KGaA Business Overview Table 73. Merck KGaA Oncology Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Merck KGaA Oncology Treatment Drug Product Portfolio Table 75. Merck KGaA Recent Development Table 76. Roche Company Information Table 77. Roche Business Overview Table 78. Roche Oncology Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Roche Oncology Treatment Drug Product Portfolio Table 80. Roche Recent Development Table 81. Eli Lilly Company Information Table 82. Eli Lilly Business Overview Table 83. Eli Lilly Oncology Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Eli Lilly Oncology Treatment Drug Product Portfolio Table 85. Eli Lilly Recent Development Table 86. Pfizer Company Information Table 87. Pfizer Business Overview Table 88. Pfizer Oncology Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Pfizer Oncology Treatment Drug Product Portfolio Table 90. Pfizer Recent Development Table 91. Bayer Company Information Table 92. Bayer Business Overview Table 93. Bayer Oncology Treatment Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Bayer Oncology Treatment Drug Product Portfolio Table 95. Bayer Recent Development Table 96. Amgen Company Information Table 97. Amgen Business Overview Table 98. Amgen Oncology Treatment Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Amgen Oncology Treatment Drug Product Portfolio Table 100. Amgen Recent Development Table 101. AbbVie Company Information Table 102. AbbVie Business Overview Table 103. AbbVie Oncology Treatment Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. AbbVie Oncology Treatment Drug Product Portfolio Table 105. AbbVie Recent Development Table 106. AstraZeneca Company Information Table 107. AstraZeneca Business Overview Table 108. AstraZeneca Oncology Treatment Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. AstraZeneca Oncology Treatment Drug Product Portfolio Table 110. AstraZeneca Recent Development Table 111. Otsuka Company Information Table 112. Otsuka Business Overview Table 113. Otsuka Oncology Treatment Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Otsuka Oncology Treatment Drug Product Portfolio Table 115. Otsuka Recent Development Table 116. Merck & Co. Company Information Table 117. Merck & Co. Business Overview Table 118. Merck & Co. Oncology Treatment Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Merck & Co. Oncology Treatment Drug Product Portfolio Table 120. Merck & Co. Recent Development Table 121. Ipsen Company Information Table 122. Ipsen Business Overview Table 123. Ipsen Oncology Treatment Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Ipsen Oncology Treatment Drug Product Portfolio Table 125. Ipsen Recent Development Table 126. Gilead Sciences Company Information Table 127. Gilead Sciences Business Overview Table 128. Gilead Sciences Oncology Treatment Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Gilead Sciences Oncology Treatment Drug Product Portfolio Table 130. Gilead Sciences Recent Development Table 131. Celgene Company Information Table 132. Celgene Business Overview Table 133. Celgene Oncology Treatment Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Celgene Oncology Treatment Drug Product Portfolio Table 135. Celgene Recent Development Table 136. Bristol-Myers Squibb Company Information Table 137. Bristol-Myers Squibb Business Overview Table 138. Bristol-Myers Squibb Oncology Treatment Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Bristol-Myers Squibb Oncology Treatment Drug Product Portfolio Table 140. Bristol-Myers Squibb Recent Development Table 141. Biogen Idec Company Information Table 142. Biogen Idec Business Overview Table 143. Biogen Idec Oncology Treatment Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Biogen Idec Oncology Treatment Drug Product Portfolio Table 145. Biogen Idec Recent Development Table 146. Astellas Company Information Table 147. Astellas Business Overview Table 148. Astellas Oncology Treatment Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Astellas Oncology Treatment Drug Product Portfolio Table 150. Astellas Recent Development Table 151. North America Oncology Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 152. North America Oncology Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 153. North America Oncology Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 154. North America Oncology Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 155. North America Oncology Treatment Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 156. North America Oncology Treatment Drug Revenue by Country (2021-2026) & (US$ Million) Table 157. North America Oncology Treatment Drug Revenue by Country (US$ Million) & (2027-2032) Table 158. Europe Oncology Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 159. Europe Oncology Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 160. Europe Oncology Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 161. Europe Oncology Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 162. Europe Oncology Treatment Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. Europe Oncology Treatment Drug Revenue by Country (2021-2026) & (US$ Million) Table 164. Europe Oncology Treatment Drug Revenue by Country (US$ Million) & (2027-2032) Table 165. China Oncology Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 166. China Oncology Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 167. China Oncology Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 168. China Oncology Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 169. Asia Oncology Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 170. Asia Oncology Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 171. Asia Oncology Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 172. Asia Oncology Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 173. Asia Oncology Treatment Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 174. Asia Oncology Treatment Drug Revenue by Region (US$ Million) & (2021-2026) Table 175. Asia Oncology Treatment Drug Revenue by Region (US$ Million) & (2027-2032) Table 176. SAMEA Oncology Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 177. SAMEA Oncology Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 178. SAMEA Oncology Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 179. SAMEA Oncology Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 180. SAMEA Oncology Treatment Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 181. SAMEA Oncology Treatment Drug Revenue by Country (2021-2026) & (US$ Million) Table 182. SAMEA Oncology Treatment Drug Revenue by Country (US$ Million) & (2027-2032) Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources Table 186. Primary Sources List of Figures Figure 1. Oncology Treatment Drug Image Figure 2. Global Oncology Treatment Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology Treatment Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Immunotherapy (Biologic Therapy) Image Figure 5. Chemotherapy Image Figure 6. Hormonal Therapy Image Figure 7. Targeted Therapy Image Figure 8. Others Image Figure 9. Global Oncology Treatment Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Oncology Treatment Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Respiratory/Lung Cancer Image Figure 12. Prostate Cancer Image Figure 13. Breast Cancer Image Figure 14. Gastrointestinal Cancer Image Figure 15. Blood Cancer Image Figure 16. Others Image Figure 17. Global Oncology Treatment Drug Market Size (US$ Million) & (2021-2032) Figure 18. Global Oncology Treatment Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Oncology Treatment Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 20. Global Oncology Treatment Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Oncology Treatment Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Oncology Treatment Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Oncology Treatment Drug Revenue Market Share by Type (2021-2032) Figure 25. Global Oncology Treatment Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Oncology Treatment Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 27. Global Oncology Treatment Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Oncology Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. North America Oncology Treatment Drug Revenue Share by Type (2021-2032) Figure 30. North America Oncology Treatment Drug Revenue Share by Application (2021-2032) Figure 31. North America Oncology Treatment Drug Revenue Share by Country (2021-2032) Figure 32. United States Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Canada Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Mexico Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Europe Oncology Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 36. Europe Oncology Treatment Drug Revenue Share by Type (2021-2032) Figure 37. Europe Oncology Treatment Drug Revenue Share by Application (2021-2032) Figure 38. Europe Oncology Treatment Drug Revenue Share by Country (2021-2032) Figure 39. Germany Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. France Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. U.K. Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Italy Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Spain Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Russia Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Netherlands Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Nordic Countries Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. China Oncology Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. China Oncology Treatment Drug Revenue Share by Type (2021-2032) Figure 49. China Oncology Treatment Drug Revenue Share by Application (2021-2032) Figure 50. Asia Oncology Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 51. Asia Oncology Treatment Drug Revenue Share by Type (2021-2032) Figure 52. Asia Oncology Treatment Drug Revenue Share by Application (2021-2032) Figure 53. Asia Oncology Treatment Drug Revenue Share by Region (2021-2032) Figure 54. Japan Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. South Korea Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. India Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Australia Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Taiwan Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Southeast Asia Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. SAMEA Oncology Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 61. SAMEA Oncology Treatment Drug Revenue Share by Type (2021-2032) Figure 62. SAMEA Oncology Treatment Drug Revenue Share by Application (2021-2032) Figure 63. SAMEA Oncology Treatment Drug Revenue Share by Country (2021-2032) Figure 64. Brazil Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Argentina Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Chile Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Colombia Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Peru Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Saudi Arabia Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Israel Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. UAE Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Turkey Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Iran Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Egypt Oncology Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Immunotherapy (Biologic Therapy)
  • Chemotherapy
  • Hormonal Therapy
  • Targeted Therapy
  • Others
Applications
  • Respiratory/Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Blood Cancer
  • Others
Companies covered
  • Takeda
  • Eisai
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck KGaA
  • Roche
  • Eli Lilly
  • Pfizer
  • Bayer
  • Amgen
  • AbbVie
  • AstraZeneca
  • Otsuka
  • Merck & Co.
  • Ipsen
  • Gilead Sciences
  • Celgene
  • Bristol-Myers Squibb
  • Biogen Idec
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oncology Treatment Drug Market by Type
  3. 1.2.1 Global Oncology Treatment Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Immunotherapy (Biologic Therapy)
  5. 1.2.3 Chemotherapy
  6. 1.2.4 Hormonal Therapy
  7. 1.2.5 Targeted Therapy
  8. 1.2.6 Others
  9. 1.3 Oncology Treatment Drug Market by Application
  10. 1.3.1 Global Oncology Treatment Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Respiratory/Lung Cancer
  12. 1.3.3 Prostate Cancer
  13. 1.3.4 Breast Cancer
  14. 1.3.5 Gastrointestinal Cancer
  15. 1.3.6 Blood Cancer
  16. 1.3.7 Others
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Oncology Treatment Drug Market Dynamics
  1. 2.1 Oncology Treatment Drug Industry Trends
  2. 2.2 Oncology Treatment Drug Industry Drivers
  3. 2.3 Oncology Treatment Drug Industry Opportunities and Challenges
  4. 2.4 Oncology Treatment Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oncology Treatment Drug Market Perspective (2021-2032)
  2. 3.2 Global Oncology Treatment Drug Growth Trends by Region
  3. 3.2.1 Global Oncology Treatment Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oncology Treatment Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Oncology Treatment Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oncology Treatment Drug Revenue by Players
  2. 4.1.1 Global Oncology Treatment Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Oncology Treatment Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oncology Treatment Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oncology Treatment Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oncology Treatment Drug Key Players Headquarters & Area Served
  7. 4.4 Global Oncology Treatment Drug Players, Product Type & Application
  8. 4.5 Global Oncology Treatment Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oncology Treatment Drug Market CR5 and HHI
  11. 4.6.3 2025 Oncology Treatment Drug Tier 1, Tier 2, and Tier 3
5 Oncology Treatment Drug Market Size by Type
  1. 5.1 Global Oncology Treatment Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oncology Treatment Drug Revenue by Type (2021-2032)
  3. 5.3 Global Oncology Treatment Drug Revenue Market Share by Type (2021-2032)
6 Oncology Treatment Drug Market Size by Application
  1. 6.1 Global Oncology Treatment Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oncology Treatment Drug Revenue by Application (2021-2032)
  3. 6.3 Global Oncology Treatment Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Oncology Treatment Drug Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Eisai
  8. 7.2.1 Eisai Company Information
  9. 7.2.2 Eisai Business Overview
  10. 7.2.3 Eisai Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eisai Oncology Treatment Drug Product Portfolio
  12. 7.2.5 Eisai Recent Developments
  13. 7.3 Teva
  14. 7.3.1 Teva Company Information
  15. 7.3.2 Teva Business Overview
  16. 7.3.3 Teva Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Teva Oncology Treatment Drug Product Portfolio
  18. 7.3.5 Teva Recent Developments
  19. 7.4 Sanofi
  20. 7.4.1 Sanofi Company Information
  21. 7.4.2 Sanofi Business Overview
  22. 7.4.3 Sanofi Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sanofi Oncology Treatment Drug Product Portfolio
  24. 7.4.5 Sanofi Recent Developments
  25. 7.5 Johnson & Johnson
  26. 7.5.1 Johnson & Johnson Company Information
  27. 7.5.2 Johnson & Johnson Business Overview
  28. 7.5.3 Johnson & Johnson Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Johnson & Johnson Oncology Treatment Drug Product Portfolio
  30. 7.5.5 Johnson & Johnson Recent Developments
  31. 7.6 Novartis
  32. 7.6.1 Novartis Company Information
  33. 7.6.2 Novartis Business Overview
  34. 7.6.3 Novartis Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novartis Oncology Treatment Drug Product Portfolio
  36. 7.6.5 Novartis Recent Developments
  37. 7.7 Merck KGaA
  38. 7.7.1 Merck KGaA Company Information
  39. 7.7.2 Merck KGaA Business Overview
  40. 7.7.3 Merck KGaA Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Merck KGaA Oncology Treatment Drug Product Portfolio
  42. 7.7.5 Merck KGaA Recent Developments
  43. 7.8 Roche
  44. 7.8.1 Roche Company Information
  45. 7.8.2 Roche Business Overview
  46. 7.8.3 Roche Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Roche Oncology Treatment Drug Product Portfolio
  48. 7.8.5 Roche Recent Developments
  49. 7.9 Eli Lilly
  50. 7.9.1 Eli Lilly Company Information
  51. 7.9.2 Eli Lilly Business Overview
  52. 7.9.3 Eli Lilly Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Eli Lilly Oncology Treatment Drug Product Portfolio
  54. 7.9.5 Eli Lilly Recent Developments
  55. 7.10 Pfizer
  56. 7.10.1 Pfizer Company Information
  57. 7.10.2 Pfizer Business Overview
  58. 7.10.3 Pfizer Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Pfizer Oncology Treatment Drug Product Portfolio
  60. 7.10.5 Pfizer Recent Developments
  61. 7.11 Bayer
  62. 7.11.1 Bayer Company Information
  63. 7.11.2 Bayer Business Overview
  64. 7.11.3 Bayer Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Bayer Oncology Treatment Drug Product Portfolio
  66. 7.11.5 Bayer Recent Developments
  67. 7.12 Amgen
  68. 7.12.1 Amgen Company Information
  69. 7.12.2 Amgen Business Overview
  70. 7.12.3 Amgen Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Amgen Oncology Treatment Drug Product Portfolio
  72. 7.12.5 Amgen Recent Developments
  73. 7.13 AbbVie
  74. 7.13.1 AbbVie Company Information
  75. 7.13.2 AbbVie Business Overview
  76. 7.13.3 AbbVie Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 AbbVie Oncology Treatment Drug Product Portfolio
  78. 7.13.5 AbbVie Recent Developments
  79. 7.14 AstraZeneca
  80. 7.14.1 AstraZeneca Company Information
  81. 7.14.2 AstraZeneca Business Overview
  82. 7.14.3 AstraZeneca Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 AstraZeneca Oncology Treatment Drug Product Portfolio
  84. 7.14.5 AstraZeneca Recent Developments
  85. 7.15 Otsuka
  86. 7.15.1 Otsuka Company Information
  87. 7.15.2 Otsuka Business Overview
  88. 7.15.3 Otsuka Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Otsuka Oncology Treatment Drug Product Portfolio
  90. 7.15.5 Otsuka Recent Developments
  91. 7.16 Merck & Co.
  92. 7.16.1 Merck & Co. Company Information
  93. 7.16.2 Merck & Co. Business Overview
  94. 7.16.3 Merck & Co. Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Merck & Co. Oncology Treatment Drug Product Portfolio
  96. 7.16.5 Merck & Co. Recent Developments
  97. 7.17 Ipsen
  98. 7.17.1 Ipsen Company Information
  99. 7.17.2 Ipsen Business Overview
  100. 7.17.3 Ipsen Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Ipsen Oncology Treatment Drug Product Portfolio
  102. 7.17.5 Ipsen Recent Developments
  103. 7.18 Gilead Sciences
  104. 7.18.1 Gilead Sciences Company Information
  105. 7.18.2 Gilead Sciences Business Overview
  106. 7.18.3 Gilead Sciences Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Gilead Sciences Oncology Treatment Drug Product Portfolio
  108. 7.18.5 Gilead Sciences Recent Developments
  109. 7.19 Celgene
  110. 7.19.1 Celgene Company Information
  111. 7.19.2 Celgene Business Overview
  112. 7.19.3 Celgene Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Celgene Oncology Treatment Drug Product Portfolio
  114. 7.19.5 Celgene Recent Developments
  115. 7.20 Bristol-Myers Squibb
  116. 7.20.1 Bristol-Myers Squibb Company Information
  117. 7.20.2 Bristol-Myers Squibb Business Overview
  118. 7.20.3 Bristol-Myers Squibb Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Bristol-Myers Squibb Oncology Treatment Drug Product Portfolio
  120. 7.20.5 Bristol-Myers Squibb Recent Developments
  121. 7.21 Biogen Idec
  122. 7.21.1 Biogen Idec Company Information
  123. 7.21.2 Biogen Idec Business Overview
  124. 7.21.3 Biogen Idec Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Biogen Idec Oncology Treatment Drug Product Portfolio
  126. 7.21.5 Biogen Idec Recent Developments
  127. 7.22 Astellas
  128. 7.22.1 Astellas Company Information
  129. 7.22.2 Astellas Business Overview
  130. 7.22.3 Astellas Oncology Treatment Drug Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Astellas Oncology Treatment Drug Product Portfolio
  132. 7.22.5 Astellas Recent Developments
8 North America
  1. 8.1 North America Oncology Treatment Drug Revenue (2021-2032)
  2. 8.2 North America Oncology Treatment Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Oncology Treatment Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Oncology Treatment Drug Revenue by Type (2027-2032)
  5. 8.3 North America Oncology Treatment Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Oncology Treatment Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Oncology Treatment Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Oncology Treatment Drug Revenue by Application (2027-2032)
  9. 8.5 North America Oncology Treatment Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Oncology Treatment Drug Revenue by Country
  11. 8.6.1 North America Oncology Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oncology Treatment Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Oncology Treatment Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Oncology Treatment Drug Revenue (2021-2032)
  2. 9.2 Europe Oncology Treatment Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oncology Treatment Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oncology Treatment Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Oncology Treatment Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oncology Treatment Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oncology Treatment Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oncology Treatment Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Oncology Treatment Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oncology Treatment Drug Revenue by Country
  11. 9.6.1 Europe Oncology Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oncology Treatment Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oncology Treatment Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Oncology Treatment Drug Revenue (2021-2032)
  2. 10.2 China Oncology Treatment Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Oncology Treatment Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Oncology Treatment Drug Revenue by Type (2027-2032)
  5. 10.3 China Oncology Treatment Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Oncology Treatment Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Oncology Treatment Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Oncology Treatment Drug Revenue by Application (2027-2032)
  9. 10.5 China Oncology Treatment Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oncology Treatment Drug Revenue (2021-2032)
  2. 11.2 Asia Oncology Treatment Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oncology Treatment Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oncology Treatment Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Oncology Treatment Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oncology Treatment Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oncology Treatment Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oncology Treatment Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Oncology Treatment Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oncology Treatment Drug Revenue by Country
  11. 11.6.1 Asia Oncology Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oncology Treatment Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oncology Treatment Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oncology Treatment Drug Revenue (2021-2032)
  2. 12.2 SAMEA Oncology Treatment Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oncology Treatment Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oncology Treatment Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oncology Treatment Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oncology Treatment Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oncology Treatment Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oncology Treatment Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oncology Treatment Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oncology Treatment Drug Revenue by Country
  11. 12.6.1 SAMEA Oncology Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oncology Treatment Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oncology Treatment Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst